| |  Online-Ressource |
|---|
| Verfasst von: | Longuespée, Rémi [VerfasserIn]  |
|---|
| | Kunz, Julia [VerfasserIn] |
|---|
| | Fresnais, Margaux [VerfasserIn] |
|---|
| | Foerster, Kathrin [VerfasserIn] |
|---|
| | Burhenne, Jürgen [VerfasserIn] |
|---|
| | Thomas, Michael [VerfasserIn] |
|---|
| | Kazdal, Daniel [VerfasserIn] |
|---|
| | Stenzinger, Albrecht [VerfasserIn] |
|---|
| | Christopoulos, Petros [VerfasserIn] |
|---|
| | Haefeli, Walter E. [VerfasserIn] |
|---|
| Titel: | Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome |
|---|
| Titelzusatz: | a case report |
|---|
| Verf.angabe: | Rémi Longuespée, Julia Kunz, Margaux Fresnais, Kathrin I. Foerster, Jürgen Burhenne, Michael Thomas, Daniel Kazdal, Albrecht Stenzinger, Petros Christopoulos, Walter E. Haefeli |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | January 2024 |
|---|
| Umfang: | 6 S. |
|---|
| Fussnoten: | Erstveröffentlichung: 10. Oktober 2023 ; Gesehen am 06.02.2024 |
|---|
| Titel Quelle: | Enthalten in: British journal of clinical pharmacology |
|---|
| Ort Quelle: | Oxford : Wiley-Blackwell, 1974 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 90(2024), 1, Seite 344-349 |
|---|
| ISSN Quelle: | 1365-2125 |
|---|
| Abstract: | Short bowel syndrome (SBS) following extensive intestinal resection is often characterized by impaired absorption of orally administered drugs, including tyrosine kinase inhibitors (TKI). We report the case of a patient with EGFR-mutated non-small cell lung carcinoma treated with 80 mg/day of the TKI osimertinib who achieved partial response of the tumour, but was subsequently subjected to a double-barrelled jejunostomy due to ileus. Due to the development of SBS after the bypass surgery, plasma concentrations of osimertinib were monitored using mass spectrometry. The therapeutic drug monitoring confirmed a malabsorption of osimertinib in the patient (108 ng/mL, which is below the 5th percentile of the expected plasma concentration) and was useful to guide adjustments of TKI dosing in order to achieve adequate blood levels (161 ng/mL after increase of the dose to 120 mg/day) in order to maintain tumour control. |
|---|
| DOI: | doi:10.1111/bcp.15924 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1111/bcp.15924 |
|---|
| | kostenfrei: Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bcp.15924 |
|---|
| | DOI: https://doi.org/10.1111/bcp.15924 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | LC-MS/MS |
|---|
| | MALDI-MS/MS |
|---|
| | non-small cell lung cancer |
|---|
| | osimertinib |
|---|
| | short bowel syndrome |
|---|
| | therapeutic drug monitoring |
|---|
| K10plus-PPN: | 1880052644 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome / Longuespée, Rémi [VerfasserIn]; January 2024 (Online-Ressource)
